Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated high-sensitivity troponin T
Clicks: 1
ID: 323373
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #162 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Elevated high-sensitivity troponin T (hs-cTnT) levels are frequently observed in cancer patients, yet their clinical significance often remains unclear. In particular, the prevalence of obstructive coronary artery disease (CAD) as an underlying cause is insufficiently defined. Methods In this single-center cohort study, 810 asymptomatic cancer patients with elevated hs-cTnT presenting to a cardio-oncology clinic between 2016 and 2023 were analyzed. All patients underwent a prospective structured cardiovascular assessment including clinical evaluation, echocardiography, and biomarker analysis at standardized follow-up appointments. In cases of unexplained troponin elevation, systematic diagnostic work-up for obstructive CAD was performed. Predictors of the presence or absence of obstructive CAD were analyzed using logistic regression. Oncologic therapies were classified according to ESC guidelines regarding cardiotoxic risk. Results Among 810 patients, 470 (58.0%) underwent further evaluation for suspected CAD due to unexplained hs-cTnT elevation. Of these, 47 patients (10.0%) had a relevant obstructive CAD requiring PCI, whereas 90.0% showed no significant coronary stenosis. Independent predictors of the absence of relevant CAD included younger age, female sex, normal NT-proBNP levels, and preserved left ventricular ejection fraction. Notably, 78.3% of patients without obstructive CAD were receiving oncologic therapies associated with moderate or high cardiotoxic risk. Conclusions In asymptomatic cancer patients, elevated hs-cTnT is not consistently driven by obstructive CAD. While elevated hs-cTnT levels associated with a worthened outcome, non-ischemic causes, including therapy- or tumor-related myocardial injury, appear to predominate. These findings highlight the need for individualized risk stratification and careful interpretation of cardiac biomarkers in oncology patients.
| Reference Key |
openalex_W7172269032
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | J Brauer, C Stengele, S W Romann, L F Entenmann, D Finke, H A Katus, E Giannitsis, N Frey, L H Lehmann |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.180
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.